Vaxcyte Inc [PCVX] stock is trading at $33.47, up 5.42%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PCVX shares have gain 7.97% over the last week, with a monthly amount glided 4.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on September 12, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $38. On December 20, 2024, Goldman initiated with a Buy rating and assigned a price target of $135 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $69 on December 07, 2023. TD Cowen initiated its recommendation with a Outperform. Needham reiterated a Buy rating for this stock on January 03, 2023, and upped its price target to $58. In a note dated December 15, 2022, Guggenheim initiated a Buy rating and provided a target price of $66 on this stock.
Vaxcyte Inc [PCVX] stock has fluctuated between $27.66 and $118.62 over the past year. Currently, Wall Street analysts expect the stock to reach $124 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $33.47 at the most recent close of the market. An investor can expect a potential return of 270.48% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.17 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.09 points at the first support level, and at 30.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.28, and for the 2nd resistance point, it is at 35.08.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 11.11. In addition, the Quick Ratio stands at 11.11 and the Cash Ratio stands at 1.99.
Transactions by insiders
Recent insider trading involved Eydelman Mikhail, SVP, GEN COUNSEL & CORP SEC, that happened on Mar 05 ’25 when 5000.0 shares were sold. Officer, Eydelman Mikhail completed a deal on Mar 05 ’25 to buy 5000.0 shares. Meanwhile, CHIEF OPERATING OFFICER Wassil Jim sold 8000.0 shares on Mar 03 ’25.
